How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,900 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update Full Text available with Trip Pro

Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update 30332601 2018 11 14 1911-6470 12 10 2018 Oct Canadian Urological Association journal = Journal de l'Association des urologues du Canada Can Urol Assoc J Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. 303-312 10.5489/cuaj.5616 Nickel J Curtis JC Department of Urology, Queen's (...) University, Kingston, ON, Canada. Aaron Lorne L Service d'Urologie and Centre de la Prostate, Longueuil, QC, Canada. Barkin Jack J Division of Urology, University of Toronto, Humber River Hospital, Toronto, ON, Canada. Elterman Dean D Division of Urology, University of Toronto, Toronto, ON, Canada. Nachabé Mahmoud M Service d'Urologie and Centre de la Prostate, Longueuil, QC, Canada. Zorn Kevin C KC Université de Montréal, Montreal, QC, Canada. eng Journal Article Canada Can Urol Assoc J 101312644 1911

2018 Canadian Urological Association Journal

202. Inhibitory effects of Pycnogenol®, a pine bark extract, in a rat model of testosterone propionate-induced benign prostatic hyperplasia Full Text available with Trip Pro

Inhibitory effects of Pycnogenol®, a pine bark extract, in a rat model of testosterone propionate-induced benign prostatic hyperplasia Benign prostate hyperplasia (BPH) is a male reproductive disease that has gained increasing importance in recent years. The present study investigated whether Pycnogenol® (PYC), a standardized French maritime pine bark extract, could prevent BPH induced by testosterone propionate (TP) in rats. Male Sprague-Dawley rats were randomly divided into five groups (...) of six rats. One group was used as a normal control rats and the other groups received subcutaneous injections of TP for 4 weeks to induce BPH. In the two treatment groups, PYC (20 or 40 mg/kg) was administered daily for 4 weeks by oral gavage concurrently with the induction of TP. All rats were sacrificed at the scheduled termination time, the prostates were weighed, and histopathologic examinations were conducted. Dihydrotestosterone (DHT) levels in serum and the prostate were measured

2018 Laboratory animal research

203. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia Full Text available with Trip Pro

Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia Rezum is a minimally invasive transurethral water vapour therapy for benign prostatic enlargement which uses thermal energy for treatment. The short-term results show it to have good outcomes with a potential for outpatient-based treatment preserving sexual function. This review serves to provide an overview of the technique and evaluate its safety and efficacy.

2018 Therapeutic advances in urology

204. Association between Diabetes Mellitus and Hypertension in Benign Prostatic Hyperplasia Patients Full Text available with Trip Pro

Association between Diabetes Mellitus and Hypertension in Benign Prostatic Hyperplasia Patients 29692388 2018 12 11 2018 12 11 2542-5641 131 9 2018 05 05 Chinese medical journal Chin. Med. J. Association between Diabetes Mellitus and Hypertension in Benign Prostatic Hyperplasia Patients. 1120-1121 10.4103/0366-6999.230730 Zeng Xian-Tao XT Department of Urology, Zhongnan Hospital of Wuhan University; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University (...) 0366-6999 IM Diabetes Complications Diabetes Mellitus Humans Hypertension complications Male Prostatic Hyperplasia complications There are no conflicts of interest 2018 4 26 6 0 2018 4 26 6 0 2018 12 12 6 0 ppublish 29692388 ChinMedJ_2018_131_9_1120_230730 10.4103/0366-6999.230730 PMC5937326 Br J Urol. 1966 Feb;38(1):18-23 4143704 J Evid Based Med. 2018 Feb;11(1):64-67 29484844 J Hypertens. 2017 May;35(5):922-944 28141660 Curr Urol Rep. 2001 Aug;2(4):297-301 12084255 Chin Med J (Engl). 2017 Aug

2018 Chinese medical journal

205. Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension? Full Text available with Trip Pro

Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension? Benign prostatic hyperplasia and hypertension are common age-related comorbidities. Although the etiology of benign prostatic hyperplasia (BPH) is still largely unresolved and poorly understood, a significant age-independent association was found between BPH and hypertension, indicating a common pathophysiological factor for both diseases. It has previously been

2018 Nutrition and metabolic insights

206. Acute urinary retention due to benign prostatic hyperplasia associated with cystitis glandularis in a 22-year-old patient Full Text available with Trip Pro

Acute urinary retention due to benign prostatic hyperplasia associated with cystitis glandularis in a 22-year-old patient A 22-year-old man has consulted in emergency for acute urinary retention and left renal colic. Bladder catheterization was performed. Symptomatic treatment was provided with no improvement. MRI showed a pseudotumoral bladder wall thickening associated with vesical floor budding with prostate median lobe infiltration. The patient got an endoscopy that concluded (...) to an inflammatory aspect of the bladder mycosa and a solid mass in the bladder neck arising. The biopsy during examination concluded to a glandular cystitis. Ultrasonography performed six months later still showed an enlarged prostate of 60g volume, post void residue of 280ml and bilateral hydronephrosis. A second cystoscopy showed an obstructive prostate with a median lobe. A transurethral resection of this lobe was performed. The pathological examination concluded to a benign prostate hyperplasia. This case

2018 The Pan African medical journal

207. Management of Obstructive Benign Prostatic Hyperplasia With a >200 mL Gland Full Text available with Trip Pro

Management of Obstructive Benign Prostatic Hyperplasia With a >200 mL Gland 29942203 2018 11 14 1523-6161 20 1 2018 Reviews in urology Rev Urol Management of Obstructive Benign Prostatic Hyperplasia With a >200 mL Gland. 43-45 10.3909/riu0795 Kelly Christopher E CE Department of Urology, NYU Langone Health New York, NY. eng Journal Article United States Rev Urol 100889067 1523-6161 2018 6 27 6 0 2018 6 27 6 0 2018 6 27 6 1 ppublish 29942203 10.3909/riu0795 PMC6003305 BMC Surg. 2012;12 Suppl 1

2018 Reviews in urology

208. Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia Full Text available with Trip Pro

Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia To investigate whether urine levels of miRNAs that regulate the function of endothelial cells are associated with effectiveness in benign prostatic hyperplasia (BPH) patients treated with a phosphodiesterase type 5 inhibitor, tadalafil.We measured urine levels of three miRNAs (miR-21-5p, miR-126-5p & miR-155-5p) in 55 BPH patients before and after tadalafil administration

2018 Future science OA

209. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model Full Text available with Trip Pro

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model Erectile dysfunction is a common side effect of finasteride and dutasteride treatments. The objective of this study was to investigate the structural changes in the penis using a benign prostatic hyperplasia (BPH) rodent model treated with dutasteride or finasteride. Sixty male rats were divided into the following groups: C, untreated control rats; C

2018 Asian journal of andrology

210. Practice Patterns in Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia among General Practitioners: Lessons Learnt from a Greek Survey Full Text available with Trip Pro

Practice Patterns in Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia among General Practitioners: Lessons Learnt from a Greek Survey 29485099 2018 11 05 2018 11 13 2146-3131 35 3 2018 05 29 Balkan medical journal Balkan Med J Practice Patterns in Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia among General Practitioners: Lessons Learnt from a Greek Survey 287-288 10.4274/balkanmedj.2017.1659 Samarinas (...) Practitioners standards Greece Humans Lower Urinary Tract Symptoms diagnosis therapy Male Middle Aged Practice Patterns, Physicians' Prostatic Hyperplasia complications diagnosis Quality of Life Surveys and Questionnaires 2018 2 28 6 0 2018 2 28 6 0 2018 11 6 6 0 ppublish 29485099 10.4274/balkanmedj.2017.1659 PMC5981131 Int J Clin Pract. 2013 Feb;67(2):114-9 23305473 Curr Opin Urol. 2008 Jan;18(1):56-60 18090491 BJU Int. 2008 May;101(9):1111-8 18279447 Eur Urol. 2015 Jun;67(6):1099-1109 25613154 Eur Urol

2018 Balkan medical journal

211. Assessing the Safety and Efficacy of the ClearRingâ„¢ Implant for the Treatment of Benign Prostatic Hyperplasia in a Canine Model Full Text available with Trip Pro

Assessing the Safety and Efficacy of the ClearRingâ„¢ Implant for the Treatment of Benign Prostatic Hyperplasia in a Canine Model Transurethral resection of the prostate is the most common procedure for the treatment of benign prostatic hyperplasia (BPH). Although effective, transurethral resection of the prostate can be associated with side effects including prolonged recovery, storage and voiding symptoms, risk of acute urinary retention.In this study, we describe a new minimally invasive (...) and no severe adverse events were observed. There was no evidence of prostatic hyperplasia associated to ring implantation. Partial epithelial coverage of the implant surface was observed without evidence of encrustation.The ClearRing™ implant seems a feasible minimally invasive procedure for relieving lower urinary track symptoms due to BPH.

2018 Current urology

212. Aquablation therapy for symptomatic benign prostatic hyperplasia: single center experience in 47 patients. Full Text available with Trip Pro

Aquablation therapy for symptomatic benign prostatic hyperplasia: single center experience in 47 patients. To report procedure process improvements and confirm the preserved safety and short-term effectiveness of a second-generation Aquablation device for the treatment of lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) in 47 consecutive patients at a single institution.Aquablation was performed in 47 patients with symptomatic BPH at a single institution (...) . Baseline, peri-operative and 3-month urinary function data were collected.The mean (range) patient age was 66 (50-79) years, and transrectal ultrasonography-measured prostate volume was 48 (20-118) mL. A median lobe was present in 25 patients (53%) and eight patients had catheter-dependent urinary retention. The mean (range) total procedure time was 35 (13-128) min and the tissue resection time was 4 (1-10) min. Five Clavien-Dindo grade I/II and five Clavien-Dindo grade III complications were recorded

2018 BJU international

213. Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia. (Abstract)

Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia. The enzyme 5-α reductase type 2 (5-AR 2) plays a key role in the development and maintenance of the prostate gland. We evaluated the level 5-AR 2 protein expression and the relationship between methylation of the 5-AR 2 gene-promoter and 5-AR 2 protein expression of benign prostatic hyperplasia (BPH).A total of 37 prostate samples were evaluated (...) . These included 22 samples from men undergoing transurethral prostate resections and 15 non-cancerous transition-zone human prostate tissue samples taken following radical prostatectomy. We quantified 5-AR 2 protein expression and gene-promoter methylation status using common assay procedures. Clinical variables included age, body mass index (BMI), prostate-specific antigen (PSA) levels, lipid profiles, and prostate volumes. Univariate and multivariate statistical analyses were performed followed by stepwise

2018 World journal of urology

214. Anti-Inflammatory and Antioxidant Effects of Kelong-Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats. Full Text available with Trip Pro

Anti-Inflammatory and Antioxidant Effects of Kelong-Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats. Benign prostatic hyperplasia (BPH) is a common disease in the current ageing male population. This research aims to study the effects of Kelong-Capsules (KLC) on testosterone-induced BPH. Thirty rats were randomly divided into normal group, model group, and three treatment groups. Three treatment groups were given KLC (3.6 g/kg), KLC (7.2 g/kg), and finasteride (0.9 mg/kg (...) ), respectively, for 28 days after establishing the animal model. The BPH rat models were evaluated by Traditional Chinese Medicine (TCM) symptoms and prostate index (PI). Results indicated that three treatment groups all alleviated the pathological changes of prostate and kidney at different levels. Compared with the model group, the PI of the groups treated with KLC (7.2 g/kg) and finasteride decreased significantly. The expressions of NF-E2 related factor 2 (Nrf-2) and quinine oxidoreductase (NQO1

2018 Evidence-based Complementary and Alternative Medicine (eCAM)

215. Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study. (Abstract)

Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study. This retrospective cohort study evaluated the association between gout and the risk of benign prostatic hyperplasia among men by using data from Taiwan's National Health Insurance Research Database.Population-based representative insurance (outpatient and inpatient) claims data of 29,269 patients with gout and 29,269 matched patients without gout (1:1 ratio) for the period of 1997-2010 in Taiwan (...) were identified. The association between gout and benign prostatic hyperplasia was evaluated using the Cox proportional hazards model. The associations of age by gout and gout phenotypes with benign prostatic hyperplasia risk were estimated.Patients with gout had a higher incidence rate of benign prostatic hyperplasia than those in the matched gout-free group (19.62 vs. 10.11 events per 1000 person-years). Compared with the gout-free group, the adjusted hazard ratios (HRs) (95% confidence intervals

2018 Prostate cancer and prostatic diseases

216. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. Full Text available with Trip Pro

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. Male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is common in men and can have negative effects on quality of life (QoL). It is the hope that this Guideline becomes a reference on the effective evidence-based surgical management of LUTS/BPH.The evidence team searched Ovid MEDLINE, the Cochrane Library, and the Agency for Healthcare Research (...) , evidence-based recommendations regarding management of LUTS/BPH utilizing surgery and minimally invasive surgical therapies; additional statements are made regarding diagnostic and pre-operative tests. Clinical statements are made in comparison to what is generally accepted as the gold standard (i.e. transurethral resection of the prostate [TURP]-monopolar and/or bipolar). This guideline is designed to be used in conjunction with the associated treatment algorithm.The prevalence and the severity

2018 Journal of Urology

217. Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: A multi-center, prospective, open-label, single-arm, phase IV trial. (Abstract)

Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: A multi-center, prospective, open-label, single-arm, phase IV trial. To evaluate the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia (BPH).This was a 12-week, single-arm, open-label, prospective, multicenter study. The study included men aged 50 years or older with nocturia (≥2 events/night) based on a voiding diary, an International Prostate

2018 Urology

218. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study. (Abstract)

Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study. Few studies discussed the link between benign prostatic hyperplasia (BPH) and bladder cancer. We performed this cohort study to investigate whether there is an association between BPH and subsequent risk of bladder cancer.We identified 35,092 study subjects including 17546 BPH patients and 17546 comparisons from the National Health Insurance database. The comparison cohort

2018 World journal of urology

219. A Randomized, Placebo-Controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients with Benign Prostatic Hyperplasia (BPH). Full Text available with Trip Pro

A Randomized, Placebo-Controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients with Benign Prostatic Hyperplasia (BPH). To evaluate the efficacy and safety of three dosing schemes of GV1001 in patients with benign prostatic hyperplasia (BPH).Eligible patients were men aged ≥50 years, with an International Prostate Symptom Score (IPSS) of ≥13, maximum urinary flow rate (Qmax ) of 5-15 mL/s, post-void residual urine volume (PVR) of ≤200 mL (...) , and prostate volume of ≥30 mL. After a 4 week run-in period, patients were randomly assigned to one of three treatment schedules: Group 1, GV1001 0.4 mg, 2-week interval; Group 2, GV1001 0.56 mg, 2-week interval; Group 3, GV1001 0.56 mg, 4-week interval) or placebo (Group 4). The eligible patients were administered GV1001 or placebo, for a total of seven intradermal injections that were administered at 2-week intervals at weeks 0, 2, 4, 6, 8, 10, and 12. Treatment continued for 12 weeks, and efficacy

2018 BJU international Controlled trial quality: predicted high

220. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. (Abstract)

Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. Benign prostate hyperplasia (BPH) is the most common disease among aging males, but no reports have addressed the prevalence of BPH in Zhengzhou. Therefore, we aimed to understand the prevalence of BPH in men aged 40 years or older in Zhengzhou's rural areas through a cross-sectional study and analyzed the correlation with epidemiologic factors and the heritability (...) % in men aged 80 years or older. The average volume of the prostate was 17.16 ± 7.96 mL, and the average IPSS was 5.89 ± 5.91. The analysis of the correlation between the associated risk factors and BPH revealed that prostatitis and a history of prostatic hyperplasia were significant factors. Obesity, smoking, drinking, diabetes, and hypertension were not correlated with BPH. Of the 94 first-degree relatives of the cases, 53 had BPH (56.38%); of the 106 first-degree relatives of the controls, five had

2018 Prostate

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>